Edges in Network
| Network | GSE16446_egf1520 - GSE16446 - SiGN-BN HC+Bootstrap |
| Network Description | Predicting the efficacy of anthracyclines in breast cancer (BC) patients: The results of the TOP trial |
| Node | BCL2A1 |
| Upstream (Parents) |
|---|
| (<<) CD274 → BCL2A1 |
| (<<) FUT4 → BCL2A1 |
| (<<) GLI3 → BCL2A1 |
| (<<) GLS → BCL2A1 |
| (<<) HLA-F → BCL2A1 |
| (<<) ICAM1 → BCL2A1 |
| (<<) ITGB7 → BCL2A1 |
| (<<) LCP1 → BCL2A1 |
| (<<) MEGF6 → BCL2A1 |
| (<<) MMP25 → BCL2A1 |
| (<<) MPP1 → BCL2A1 |
| (<<) NFKB2 → BCL2A1 |
| (<<) NFKBIE → BCL2A1 |
| (<<) PLCG2 → BCL2A1 |
| (<<) PRSS2 → BCL2A1 |
| (<<) PTAFR → BCL2A1 |
| (<<) SOCS1 → BCL2A1 |
| (<<) SOD2 → BCL2A1 |
| (<<) TGM2 → BCL2A1 |
| (<<) TMEM158 → BCL2A1 |
| (<<) TNF → BCL2A1 |
| (<<) TNFAIP3 → BCL2A1 |
| (<<) TRAF1 → BCL2A1 |
| Downstream (Children) |
|---|
| BCL2A1 → ADAM8 (>>) |
| BCL2A1 → CHST11 (>>) |
| BCL2A1 → CNIH4 (>>) |
| BCL2A1 → CSTA (>>) |
| BCL2A1 → DYRK1A (>>) |
| BCL2A1 → EFNB1 (>>) |
| BCL2A1 → F2RL1 (>>) |
| BCL2A1 → FCRLB (>>) |
| BCL2A1 → ICAM2 (>>) |
| BCL2A1 → IL1RN (>>) |
| BCL2A1 → MMP12 (>>) |
| BCL2A1 → NXT1 (>>) |
| BCL2A1 → PODXL (>>) |
| BCL2A1 → PRSS3 (>>) |
| BCL2A1 → SGMS2 (>>) |
| BCL2A1 → SMAD3 (>>) |
| BCL2A1 → SUMF1 (>>) |
| BCL2A1 → TAF9 (>>) |
| BCL2A1 → UPP1 (>>) |
| BCL2A1 → VANGL1 (>>) |
